Tearsheet

Relmada Therapeutics (RLMD)

Market Price (12/18/2025): $4.005 | Market Cap: $132.9 Mil
Sector: Health Care | Industry: Biotechnology

Relmada Therapeutics (RLMD)

Market Price (12/18/2025): $4.005
Market Cap: $132.9 Mil
Sector: Health Care
Industry: Biotechnology

Investment Highlights Why It Matters Which of these 2 stories sounds closer for this stock?

1. Generates cash flow

The stock generated 4% or more of the share price (called cash flow yield), and shows moderate 10-15% or more growth.

2. Riding a trend

Think Tesla during the pandemic of 2020 when EVs were riding a cultural high, or Nvidia in the current AI boom, or even Figma. These companies don’t have enough yield, or, enough growth, or both - however - they are riding a trend. They have momentum. These can be more volatile - they don’t have the floor of strong cash flow

0	Megatrend and thematic drivers Megatrends include Neurological & Psychiatric Health, and Precision Medicine. Themes include Depression & Mood Disorder Therapies, CNS Drug Development, Show more.	Weak multi-year price returns 3Y Excs Rtn is -50%	Very low revenue Rev LTMTotal Revenue or Sales, Last Twelve Months is 0
1			Not profitable at operating income level Op Inc LTMOperating Income, Last Twelve Months is -58 Mil
2			Stock price has recently run up significantly 6M Rtn6 month market price return is 473%, 12M Rtn12 month market price return is 1009%
3			High stock price volatility Vol 12M is 153%
4			Key risks RLMD key risks include [1] repeated Phase 3 clinical trial failures of its lead candidate, Show more.

0	Megatrend and thematic drivers Megatrends include Neurological & Psychiatric Health, and Precision Medicine. Themes include Depression & Mood Disorder Therapies, CNS Drug Development, Show more.
1	Weak multi-year price returns 3Y Excs Rtn is -50%
2	Very low revenue Rev LTMTotal Revenue or Sales, Last Twelve Months is 0
3	Not profitable at operating income level Op Inc LTMOperating Income, Last Twelve Months is -58 Mil
4	Stock price has recently run up significantly 6M Rtn6 month market price return is 473%, 12M Rtn12 month market price return is 1009%
5	High stock price volatility Vol 12M is 153%
6	Key risks RLMD key risks include [1] repeated Phase 3 clinical trial failures of its lead candidate, Show more.

Valuation, Metrics & Events

null

AI Generated Analysis | Feedback

Metric	Value	Date	Source
Number of Employees	27	12312025	Link
Total Patent Families	47	8042025	Link
NDV-01 Phase 2 Six-Month Complete Response Rate	91%	9102025	Link
NDV-01 Phase 2 Nine-Month Overall Response Rate	92%	11042025	Link
Number of Recruiting Clinical Trials	1	11072025	Link
Number of Drug Candidates in Pipeline	2	9102025	Link

Upcoming
3/26/2026	Earnings Release	Rev: - EPS: -

RLMD Stock

Return (1M):

null

Why The Stock Moved

Qualitative Assessment

AI Generated Analysis | Feedback

Here are the key points explaining the significant stock movement for Relmada Therapeutics (RLMD) from approximately August 31, 2025, to December 18, 2025:

1. Continued Positive Clinical Data for NDV-01: Relmada Therapeutics sustained positive momentum with its lead candidate, NDV-01, for non-muscle invasive bladder cancer (NMIBC). Following impressive 6-month follow-up data reported on August 7, 2025, showing a 91% complete response rate, the company further announced positive 9-month follow-up data on November 13, 2025, demonstrating a 92% complete response rate. These consistent and strong results significantly bolstered confidence in the drug's efficacy.

2. Favorable FDA Regulatory Alignment: A major catalyst was the positive feedback received from the FDA. On November 4, 2025, Relmada announced that the FDA provided clarity and support for two separate acceptable registrational study paths for NDV-01. This regulatory alignment, further detailed in the Q3 2025 financial results on November 13, 2025, with secured FDA alignment on key elements of its Phase 3 program, de-risked the development pathway and provided a clear route toward potential market approval.

3. Successful $100 Million Financing Round: On November 4, 2025, Relmada announced the pricing of a $100 million underwritten offering of common stock and pre-funded warrants. This substantial capital raise, subsequently confirmed on November 13, 2025, provided crucial funding to support company operations into 2028, specifically earmarked for advancing the NDV-01 registrational studies and the development of sepranolone.

4. Advancement and Planning of Key Pipeline Studies: Throughout the period, Relmada reiterated and detailed its plans to initiate pivotal Phase 3 studies for NDV-01 in the first half of 2026. Additionally, the company is preparing to initiate a Phase 2 study for sepranolone in Prader-Willi Syndrome, also in the first half of 2026. These concrete plans for advancing its pipeline provided investors with a clear roadmap for future value inflection points.

5. Strengthening of Clinical Leadership: On October 7, 2025, Relmada enhanced its expertise by appointing Dr. Max Kates, a distinguished Urologic Oncologist, to its Clinical Advisory Board. This strategic addition was made to support and guide the ongoing development of NDV-01, signaling a strong commitment to the program's success.

Show less

Stock Movement Drivers

Fundamental Drivers

The 165.6% change in RLMD stock from 9/17/2025 to 12/17/2025 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).

	9172025	12172025	Change
Stock Price ($)	1.51	4.01	165.56%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	0.00	0.00	�
P/S Multiple	∞	∞	�
Shares Outstanding (Mil)	33.19	33.19	0.00%
Cumulative Contribution			�

LTM = Last Twelve Months as of date shown

Market Drivers

9/17/2025 to 12/17/2025

	Return	Correlation
RLMD	165.6%
Market (SPY)	1.9%	18.3%
Sector (XLV)	12.1%	26.0%

Fundamental Drivers

The 472.9% change in RLMD stock from 6/18/2025 to 12/17/2025 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).

	6182025	12172025	Change
Stock Price ($)	0.70	4.01	472.94%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	0.00	0.00	�
P/S Multiple	∞	∞	�
Shares Outstanding (Mil)	30.41	33.19	-9.15%
Cumulative Contribution			�

LTM = Last Twelve Months as of date shown

Market Drivers

6/18/2025 to 12/17/2025

	Return	Correlation
RLMD	472.9%
Market (SPY)	12.7%	7.2%
Sector (XLV)	16.0%	18.6%

Fundamental Drivers

The 1008.7% change in RLMD stock from 12/17/2024 to 12/17/2025 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).

	12172024	12172025	Change
Stock Price ($)	0.36	4.01	1008.65%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	0.00	0.00	�
P/S Multiple	∞	∞	�
Shares Outstanding (Mil)	30.17	33.19	-10.00%
Cumulative Contribution			�

LTM = Last Twelve Months as of date shown

Market Drivers

12/17/2024 to 12/17/2025

	Return	Correlation
RLMD	1008.7%
Market (SPY)	12.1%	10.1%
Sector (XLV)	11.9%	8.0%

Fundamental Drivers

The 19.0% change in RLMD stock from 12/18/2022 to 12/17/2025 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).

	12182022	12172025	Change
Stock Price ($)	3.37	4.01	18.99%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	0.00	0.00	�
P/S Multiple	∞	∞	�
Shares Outstanding (Mil)	30.06	33.19	-10.40%
Cumulative Contribution			�

LTM = Last Twelve Months as of date shown

Market Drivers

12/18/2023 to 12/17/2025

	Return	Correlation
RLMD	59.8%
Market (SPY)	44.9%	7.1%
Sector (XLV)	17.8%	8.0%

Return vs. Risk

Price Returns Compared

	2020	2021	2022	2023	2024	2025	Total [1]
Returns
RLMD Return	-18%	-30%	-85%	19%	-87%	765%	-88%
Peers Return	�	�	�	�	�	�	�
S&P 500 Return	16%	27%	-19%	24%	23%	14%	108%
Monthly Win Rates [3]
RLMD Win Rate	50%	50%	50%	50%	33%	67%
Peers Win Rate	�	�	�	�	�	�
S&P 500 Win Rate	58%	75%	42%	67%	75%	73%
Max Drawdowns [4]
RLMD Max Drawdown	-39%	-47%	-90%	-36%	-91%	-52%
Peers Max Drawdown	�	�	�	�	�	�
S&P 500 Max Drawdown	-31%	-1%	-25%	-1%	-2%	-15%

[1] Cumulative total returns since the beginning of 2020
[2] Peers: VRTX, ACSB, AIXC, ALPS, APRI.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 12/17/2025 (YTD)

How Low Can It Go

Unique Key	Event	RLMD	S&P 500
2022 Inflation Shock	2022 Inflation Shock
2022 Inflation Shock% Loss	% Loss	-94.5%	-25.4%
2022 Inflation Shock% Gain to Breakeven	% Gain to Breakeven	1710.1%	34.1%
2022 Inflation ShockTime to Breakeven	Time to Breakeven	Not Fully Recovered days	464 days
2020 Covid Pandemic	2020 Covid Pandemic
2020 Covid Pandemic% Loss	% Loss	-52.6%	-33.9%
2020 Covid Pandemic% Gain to Breakeven	% Gain to Breakeven	110.8%	51.3%
2020 Covid PandemicTime to Breakeven	Time to Breakeven	Not Fully Recovered days	148 days
2018 Correction	2018 Correction
2018 Correction% Loss	% Loss	-37.5%	-19.8%
2018 Correction% Gain to Breakeven	% Gain to Breakeven	60.1%	24.7%
2018 CorrectionTime to Breakeven	Time to Breakeven	49 days	120 days

Compare to VRTX, ACSB, AIXC, ALPS, APRI

In The Past

Relmada Therapeutics's stock fell -94.5% during the 2022 Inflation Shock from a high on 1/12/2021. A -94.5% loss requires a 1710.1% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth over time.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Relmada Therapeutics (RLMD)

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.

AI Generated Analysis | Feedback

Here are 1-3 brief analogies for Relmada Therapeutics (RLMD):

Relmada Therapeutics is a clinical-stage biotech company with its future largely depending on one promising drug for depression, similar to how Moderna was before its vaccine breakthrough.
Relmada Therapeutics is a small biotech aiming to be a leader in CNS disorders, similar to a nascent Biogen (known for neurology drugs) but with its current focus entirely on one depression treatment.
Relmada Therapeutics is a speculative biotech company where its future rests on one breakthrough drug for depression, much like an early-stage Vertex Pharmaceuticals betting its future on its cystic fibrosis treatments.

AI Generated Analysis | Feedback

```html

REL-1017 (esmethadone): An investigational NMDA receptor modulator being developed as an adjunctive treatment for major depressive disorder (MDD).

```

AI Generated Analysis | Feedback

Relmada Therapeutics (RLMD) is a clinical-stage biopharmaceutical company focused on the development of novel therapies for central nervous system (CNS) disorders. As of the current date, the company does not have any commercialized products available for sale on the market. Therefore, Relmada Therapeutics does not have "major customers" in the traditional sense of companies or individuals purchasing its products. Its primary activities are research and development, including conducting clinical trials for its lead product candidate, REL-1017, for the treatment of Major Depressive Disorder (MDD). The company's funding primarily comes from financing activities, such as equity offerings and potential strategic partnerships or licensing agreements with larger pharmaceutical companies, rather than from product sales. If Relmada Therapeutics were to successfully commercialize a product in the future, its customers would primarily be:

Pharmaceutical Wholesalers/Distributors: Companies like McKesson (MCK), AmerisourceBergen (ABC), and Cardinal Health (CAH) would purchase the product for distribution to pharmacies and healthcare providers.
Hospitals and Healthcare Systems: Major healthcare networks and hospitals would purchase the drug for use within their facilities.
Retail and Specialty Pharmacies: Pharmacies would stock and dispense the medication to patients based on prescriptions.

AI Generated Analysis | Feedback

null

AI Generated Analysis | Feedback

Sergio Traversa, Pharm.D., MBA, Chief Executive Officer

Dr. Traversa has served as Relmada Therapeutics' Chief Executive Officer since April 2012. He was the co-founder and CEO of Medeor Inc., a pharmaceutical company spun off from Cornell University. He also was a founding partner of Ardana Capital, a pharmaceutical and biotechnology investment advisory firm. Dr. Traversa has over 25 years of experience in the healthcare sector, including management positions in the pharmaceutical industry and roles in investing and strategic advisory. He held financial analyst, portfolio management, and strategic advisory positions at U.S. investment firms such as Mehta and Isaly, Mehta Partners, ING Barings, Merlin BioMed, and Rx Capital. Previously, he was the Area Manager for Southern Europe of Therakos Inc., a cancer and immunology division of Johnson & Johnson. Before that, Dr. Traversa worked at Eli Lilly as Marketing Manager of the Hospital Business Unit and was part of the CNS team involved in the launch of Prozac and the early development of Zyprexa and Cymbalta. He began his career as a sales representative at Farmitalia Carlo Erba, which was later acquired by Pharmacia and is now part of Pfizer. Dr. Traversa also served as interim CEO and CFO of Actinium Pharmaceuticals, Inc. and is currently a board member of Actinium.

Maged Shenouda, Chief Financial Officer

Mr. Shenouda previously served as CFO and Executive Vice President of Corporate Development for AzurRx BioPharma, Inc.

Charles S. Ence, Chief Accounting and Compliance Officer

Charles Ence currently serves as Relmada Therapeutics' Chief Accounting and Compliance Officer.

Raj S. Pruthi, MD, Chief Medical Officer

Dr. Pruthi is an accomplished physician, surgeon, and clinical scientist with extensive experience in academic medicine and industry. Prior to joining Relmada, Dr. Pruthi was Chief Medical Officer at enGene Holdings Inc., where he led a global team in the development of a registrational therapeutic trial for bladder cancer. He also served as the Global Medical Affairs Leader, Bladder Cancer and Senior Medical Director, Oncology (Global – Prostate and Bladder Cancer) at Johnson and Johnson Innovative Medicine.

Paolo Manfredi, Chief Scientific Officer

Paolo Manfredi is the Chief Scientific Officer at Relmada Therapeutics.

AI Generated Analysis | Feedback

Key Business Risks for Relmada Therapeutics (RLMD)

Relmada Therapeutics, Inc. (RLMD) faces several significant risks inherent to the biotechnology sector, particularly related to clinical trial outcomes, financial stability, and regulatory hurdles.


    Clinical Trial Failures and Pipeline Risk: The most prominent risk to Relmada Therapeutics is the high rate of failure in its clinical development programs. The company recently discontinued two Phase 3 trials (Reliance II and Relight) for its lead candidate, REL-1017, intended for major depressive disorder, after interim analyses indicated they were unlikely to achieve their primary efficacy endpoints. This follows a previous failure of REL-1017 in the Phase 3 RELIANCE III study. These repeated setbacks led to a substantial decline in the company's stock value and prompted Relmada to explore strategic alternatives, including a potential sale or merger. While the company is advancing other candidates like NDV-01 for non-muscle invasive bladder cancer into Phase 3, the inherent risk of clinical trial failure remains a critical concern for its remaining pipeline.
    Financial Instability and Funding Risk: Relmada Therapeutics has consistently operated at a loss, reporting a net loss of $21.8 million in Q1 2024 and an operating loss of approximately $98.54 million over the preceding twelve months. Analysts do not anticipate the company achieving profitability in the current year. The extensive costs associated with conducting late-stage clinical trials, especially for planned Phase 3 studies of NDV-01, necessitate substantial capital. Despite holding some cash and investments, concerns exist about the sufficiency of its cash runway, with estimates suggesting a limited timeframe based on current burn rates. This financial position indicates a high probability of future capital raises, which could lead to further dilution of shareholder value. The discontinuation of the REL-1017 trials further diminishes near-term revenue potential and compounds financial uncertainty.
    Regulatory Risk and Dependence on FDA Approvals: As a clinical-stage biotechnology company, Relmada's ability to bring its drug candidates to market is contingent upon navigating complex regulatory pathways and securing approvals from health authorities like the U.S. Food and Drug Administration (FDA). While the company has received positive feedback from the FDA regarding potential registrational pathways for NDV-01, ongoing and future interactions with regulatory bodies are subject to inherent uncertainties. Any delays in gaining regulatory alignment, or failure to meet FDA requirements for efficacy and safety, could significantly impact development timelines, increase costs, and jeopardize the commercial viability of its product candidates.

AI Generated Analysis | Feedback

The emerging threat to Relmada Therapeutics stems from the rapid advancement and potential market entry of psychedelic-assisted therapies for Major Depressive Disorder (MDD) and Treatment-Resistant Depression (TRD).

Companies like Compass Pathways, among others, are in late-stage clinical trials (e.g., Phase 3 for psilocybin in TRD) and have received regulatory designations such as FDA Breakthrough Therapy. These therapies offer a fundamentally different treatment paradigm compared to Relmada's lead candidate, REL-1017, which is a daily oral medication. Psychedelic-assisted therapies have demonstrated the potential for rapid, profound, and durable antidepressant effects after only a limited number of administrations (e.g., one or two doses), which could significantly reduce or eliminate the need for chronic daily medication over extended periods.

If these single or limited-dose therapies are approved and gain market acceptance, they could disrupt the market for daily oral antidepressants by shifting patient and prescriber preferences towards therapies offering long-term efficacy without the burden of continuous daily dosing. This represents a clear emerging threat that could fundamentally alter the competitive landscape for psychiatric treatments, similar to how streaming services disrupted physical media rentals.

AI Generated Analysis | Feedback

Relmada Therapeutics, Inc. (RLMD) is a clinical-stage biotechnology company with a pipeline of product candidates targeting various central nervous system disorders and oncology. The addressable markets for their main products or services are as follows: * NDV-01 (for high-grade Non-Muscle Invasive Bladder Cancer - NMIBC): The U.S. NMIBC market is estimated to be a multi-billion dollar opportunity. Annually, 600,000 patients in the U.S. are affected by NMIBC. Global numbers for this market are projected to be higher due to increasing incidence of bladder cancer. * Sepranolone (for Tourette syndrome and Prader-Willi syndrome - PWS): For Tourette syndrome, the U.S. prevalence is approximately 350,000 patients. In the U.S., there are 20,000 patients with PWS. The global prevalence for PWS ranges from 350,000 to 400,000 patients. The company's prior lead product candidate, REL-1017, for Major Depressive Disorder (MDD), has had its Phase 3 trials discontinued due to futility.

AI Generated Analysis | Feedback

Relmada Therapeutics (RLMD) faces a significant shift in its prospective revenue drivers following the discontinuation of its lead Major Depressive Disorder (MDD) drug, REL-1017, from Phase 3 trials due to a futility assessment. This has prompted the company to explore strategic alternatives, including potential sale of assets, merger, or acquisition of new products. Consequently, future revenue growth will hinge on the successful development and potential commercialization of its remaining pipeline and any outcomes from its strategic review. Here are 3-5 expected drivers of future revenue growth for Relmada Therapeutics over the next 2-3 years, contingent on successful clinical development and strategic execution:

Advancement and Potential Commercialization of REL-P11 for Metabolic Diseases: Relmada is progressing with REL-P11, a proprietary low-dose, modified-release psilocybin formulation. Following the completion of a Phase 1 safety study, the company plans to initiate a Phase 2 study in the first half of 2025 for metabolic diseases. Positive results from this Phase 2 trial and subsequent successful clinical development could lead to its eventual commercialization, representing a new product line and significant revenue potential.
Development and Commercialization of NDV-01 for Non-Muscle Invasive Bladder Cancer (NMIBC): The company is advancing NDV-01, a controlled-release intravesical formulation, which is currently in a Phase 2 clinical trial for aggressive forms of NMIBC. Success in ongoing and future clinical trials for NDV-01, leading to regulatory approval and market entry, would create a new revenue stream in the oncology space.
Progression of Sepranolone for Neurological and Neuropsychiatric Disorders: Sepranolone, a neurosteroid epimer, is Phase 2b-ready for potential indications such as Prader-Willi Syndrome, Tourette Syndrome, and excessive tremor. Successful progression through clinical development and eventual commercialization of sepranolone would diversify Relmada's product portfolio and open new market opportunities.
Strategic Transactions and Acquisition of New Assets: With the discontinuation of REL-1017, Relmada is actively exploring strategic alternatives to maximize shareholder value, including mergers, reverse mergers, or the acquisition of assets or development rights for other products. Should Relmada successfully acquire or license promising new product candidates, these could become significant drivers of future revenue growth within the 2-3 year timeframe, depending on their stage of development.

AI Generated Analysis | Feedback

Share Issuance

  In November 2025, Relmada Therapeutics priced an underwritten offering of 40,142,000 shares of common stock and pre-funded warrants to purchase up to 5,315,000 shares, expecting to raise approximately $100 million in gross proceeds.
  The common stock was offered at $2.20 per share, and pre-funded warrants at $2.199 per pre-funded warrant.
  Net proceeds from this offering are intended to fund working capital, clinical studies, systems, and potential strategic investments.


Outbound Investments

  In early 2025, Relmada Therapeutics strategically acquired development rights to two new product candidates: NDV-01, for non-muscle invasive bladder cancer, and sepranolone, for compulsion-related disorders.
  As of February 2025, Relmada Therapeutics completed a Corporate Asset Purchase with Asarina Pharma for Tourette Syndrome Therapy Compound Rights.
  In July 2021, the company acquired development and commercial rights to a novel psilocybin and derivate program from Arbormentis LLC for all ex-Asia territories, including the U.S. and Europe.


Capital Expenditures

  Relmada Therapeutics' free cash flow, which is operating cash flow minus capital expenditures, was -$0.052 billion in 2024 and -$0.052 billion in 2023.
  The company's free cash flow was -$0.104 billion in 2022 and -$0.092 billion in 2021.

Better Bets than Relmada Therapeutics (RLMD)

	RLMD	Better Performance than RLMD
Metric	Value	INDUSTRY: Biotechnology
Total Yield	-84.2%	GILD (8.8%), REGN (8.3%), AMGN (7.9%), VRTX (3.7%), ABBV (3.4%)

	RLMD	Better Performance than RLMD
Metric	Value	SECTOR: Health Care
Total Yield	-84.2%	MRK (13.0%), JNJ (8.4%), UNH (8.1%), ABBV (3.4%), LLY (2.7%)

	RLMD	Better Performance than RLMD
Metric	Value	ALL OTHER SECTORS
Total Yield	-84.2%	GOOGL (4.6%), MSFT (3.4%), AMZN (3.0%), AAPL (3.0%), NVDA (2.2%)

null

Latest Trefis Analyses

	Title	Topic
0	DASHBOARDS
1	Relmada Therapeutics Earnings Notes
2	Day 6 of Gains Streak for Relmada Therapeutics Stock with 61% Return (vs. 412% YTD) [10/2/2025]	Notification
3	Day 6 of Gains Streak for Relmada Therapeutics Stock with 136% Return (vs. 183% YTD) [9/3/2025]	Notification

	Title
0	ARTICLES

Trade Ideas

Select past ideas related to RLMD. For more, see Trefis Trade Ideas.

Unique Key	Date	Ticker	Company	Category	Trade Strategy	6M Fwd Rtn	12M Fwd Rtn	12M Max DD
CRL_11142025_Dip_Buyer_FCFYield	11142025	CRL	Charles River Laboratories International	Dip Buy	DB \| FCFY OPMDip Buy with High FCF Yield and High Margin Buying dips for companies with high FCF yield and meaningfully high operating margin	16.8%	16.8%	-3.7%
GDRX_11142025_Dip_Buyer_High_CFO_Margins_ExInd_DE	11142025	GDRX	GoodRx	Dip Buy	DB \| CFO/Rev \| Low D/EDip Buy with High Cash Flow Margins Buying dips for companies with significant cash flows from operations and reasonable debt / market cap	-6.4%	-6.4%	-11.8%
ASTH_11142025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	11142025	ASTH	Astrana Health	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	5.2%	5.2%	-5.5%
SGRY_11142025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	11142025	SGRY	Surgery Partners	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	3.4%	3.4%	-1.4%
TFX_11072025_Dip_Buyer_FCFYield	11072025	TFX	Teleflex	Dip Buy	DB \| FCFY OPMDip Buy with High FCF Yield and High Margin Buying dips for companies with high FCF yield and meaningfully high operating margin	14.4%	14.4%	-5.1%

Unique Key	Date	Ticker	Company	Category	Trade Strategy	6M Fwd Rtn	12M Fwd Rtn	12M Max DD
CRL_11142025_Dip_Buyer_FCFYield	11142025	CRL	Charles River Laboratories International	Dip Buy	DB \| FCFY OPMDip Buy with High FCF Yield and High Margin Buying dips for companies with high FCF yield and meaningfully high operating margin	16.8%	16.8%	-3.7%
GDRX_11142025_Dip_Buyer_High_CFO_Margins_ExInd_DE	11142025	GDRX	GoodRx	Dip Buy	DB \| CFO/Rev \| Low D/EDip Buy with High Cash Flow Margins Buying dips for companies with significant cash flows from operations and reasonable debt / market cap	-6.4%	-6.4%	-11.8%
ASTH_11142025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	11142025	ASTH	Astrana Health	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	5.2%	5.2%	-5.5%
SGRY_11142025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	11142025	SGRY	Surgery Partners	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	3.4%	3.4%	-1.4%
TFX_11072025_Dip_Buyer_FCFYield	11072025	TFX	Teleflex	Dip Buy	DB \| FCFY OPMDip Buy with High FCF Yield and High Margin Buying dips for companies with high FCF yield and meaningfully high operating margin	14.4%	14.4%	-5.1%

Recent Active Movers

1 Day Top Gainers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
UDMY	Udemy	0.9	12.7%	-26.5%
TWO	Two Harbors Investment	1.2	12.1%	8.5%
IOVA	Iovance Biotherapeutics	0.9	12.0%	-65.9%
KOD	Kodiak Sciences	1.4	11.8%	171.1%
RXRX	Recursion Pharmaceuticals	2.1	11.4%	-30.8%
TTC	Toro	7.9	10.7%	2.0%
HUT	Hut 8	4.2	9.0%	96.0%
TPL	Texas Pacific Land	20.3	7.6%	-19.7%
AXGN	Axogen	1.5	7.0%	90.5%
SSII	SS Innovations International	1.1	6.7%	-25.6%

1 Day Top Losers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
NOW	ServiceNow	32.5	-80.0%	-85.2%
FDMT	4D Molecular Therapeutics	0.5	-20.1%	65.4%
IMNM	Immunome	1.7	-15.8%	86.3%
HNRG	Hallador Energy	0.7	-15.2%	51.2%
AMPX	Amprius Technologies	1.1	-14.6%	213.6%
BNTC	Benitec Biopharma	0.4	-13.1%	-14.6%
FLNC	Fluence Energy	2.4	-12.9%	16.9%
IMSR	Terrestrial Energy	0.7	-12.6%
BE	Bloom Energy	18.1	-12.1%	246.6%
BW	Babcock & Wilcox Enterprises	0.5	-12.1%	182.9%

1 Week Top Gainers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
TLRY	Tilray Brands	13.7	55.9%	-3.2%
PL	Planet Labs PBC	5.0	27.3%	307.7%
EEX	Emerald	0.9	25.9%	-2.8%
EVCM	EverCommerce	2.2	17.2%	10.4%
CNL	Collective Mining	1.1	15.8%	229.3%
ENVA	Enova International	4.1	15.8%	70.8%
IMVT	Immunovant	4.6	14.5%	8.9%
QURE	uniQure	1.3	14.3%	30.4%
INNV	InnovAge	0.8	14.2%	49.6%
PGEN	Precigen	1.2	13.4%	255.4%

1 Week Top Losers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
NOW	ServiceNow	32.5	-81.7%	-85.2%
RZLT	Rezolute	0.2	-81.6%	-59.0%
FRMI	Fermi	6.3	-41.1%
LENZ	LENZ Therapeutics	0.5	-34.6%	-43.3%
BETR	Better Home & Finance	0.5	-30.9%	292.0%
LWLG	Lightwave Logic	0.4	-29.5%	41.4%
APLD	Applied Digital	5.6	-29.0%	188.0%
CRWV	CoreWeave	31.4	-26.8%
WULF	TeraWulf	4.5	-26.6%	104.4%
BW	Babcock & Wilcox Enterprises	0.5	-26.5%	182.9%

1 Month Top Gainers

Ticker	Company	Mkt Cap (B)	1M Rtn	YTD Rtn
OLMA	Olema Pharmaceuticals	2.8	282.6%	459.2%
WVE	WAVE Life Sciences	2.7	128.5%	32.1%
ALMS	Alumis	0.8	89.8%	34.6%
NUVB	Nuvation Bio	2.9	82.4%	220.3%
SEMR	SEMrush	1.8	75.7%	-0.2%
TE	T1 Energy	0.8	70.4%
ANF	Abercrombie & Fitch	5.6	68.4%	-21.6%
CBLL	CeriBell	0.8	67.5%	-16.6%
FTRE	Fortrea	1.5	65.4%	-13.2%
VERA	Vera Therapeutics	3.1	64.7%	14.8%

1 Month Top Losers

Ticker	Company	Mkt Cap (B)	1M Rtn	YTD Rtn
NOW	ServiceNow	32.5	-81.3%	-85.2%
RZLT	Rezolute	0.2	-80.3%	-59.0%
JANX	Janux Therapeutics	0.9	-50.9%	-73.7%
FRMI	Fermi	6.3	-50.6%
AGIO	Agios Pharmaceuticals	1.5	-43.6%	-22.6%
IMSR	Terrestrial Energy	0.7	-38.9%
LENZ	LENZ Therapeutics	0.5	-36.3%	-43.3%
LWLG	Lightwave Logic	0.4	-36.3%	41.4%
UAMY	United States Antimony	0.5	-33.7%	156.5%
BETR	Better Home & Finance	0.5	-33.6%	292.0%

Recent Active Movers

1 Day Top Gainers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
UDMY	Udemy	0.9	12.7%	-26.5%
TWO	Two Harbors Investment	1.2	12.1%	8.5%
IOVA	Iovance Biotherapeutics	0.9	12.0%	-65.9%
KOD	Kodiak Sciences	1.4	11.8%	171.1%
RXRX	Recursion Pharmaceuticals	2.1	11.4%	-30.8%
TTC	Toro	7.9	10.7%	2.0%
HUT	Hut 8	4.2	9.0%	96.0%
TPL	Texas Pacific Land	20.3	7.6%	-19.7%
AXGN	Axogen	1.5	7.0%	90.5%
SSII	SS Innovations International	1.1	6.7%	-25.6%

1 Day Top Losers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
NOW	ServiceNow	32.5	-80.0%	-85.2%
FDMT	4D Molecular Therapeutics	0.5	-20.1%	65.4%
IMNM	Immunome	1.7	-15.8%	86.3%
HNRG	Hallador Energy	0.7	-15.2%	51.2%
AMPX	Amprius Technologies	1.1	-14.6%	213.6%
BNTC	Benitec Biopharma	0.4	-13.1%	-14.6%
FLNC	Fluence Energy	2.4	-12.9%	16.9%
IMSR	Terrestrial Energy	0.7	-12.6%
BE	Bloom Energy	18.1	-12.1%	246.6%
BW	Babcock & Wilcox Enterprises	0.5	-12.1%	182.9%

1 Week Top Gainers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
TLRY	Tilray Brands	13.7	55.9%	-3.2%
PL	Planet Labs PBC	5.0	27.3%	307.7%
EEX	Emerald	0.9	25.9%	-2.8%
EVCM	EverCommerce	2.2	17.2%	10.4%
CNL	Collective Mining	1.1	15.8%	229.3%
ENVA	Enova International	4.1	15.8%	70.8%
IMVT	Immunovant	4.6	14.5%	8.9%
QURE	uniQure	1.3	14.3%	30.4%
INNV	InnovAge	0.8	14.2%	49.6%
PGEN	Precigen	1.2	13.4%	255.4%

1 Week Top Losers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
NOW	ServiceNow	32.5	-81.7%	-85.2%
RZLT	Rezolute	0.2	-81.6%	-59.0%
FRMI	Fermi	6.3	-41.1%
LENZ	LENZ Therapeutics	0.5	-34.6%	-43.3%
BETR	Better Home & Finance	0.5	-30.9%	292.0%
LWLG	Lightwave Logic	0.4	-29.5%	41.4%
APLD	Applied Digital	5.6	-29.0%	188.0%
CRWV	CoreWeave	31.4	-26.8%
WULF	TeraWulf	4.5	-26.6%	104.4%
BW	Babcock & Wilcox Enterprises	0.5	-26.5%	182.9%

Peer Comparisons for Relmada Therapeutics

Peers to compare with:

Financials

	RLMD	VRTX	ACSB	AIXC	ALPS	APRI	Median
Name	Relmada .	Vertex P.	Acesis	AIxCrypto	ALPS	Aprinoia.
Mkt Price	4.01	449.52	-	2.85	0.98	-	3.43
Mkt Cap	0.1	114.9	-	-	-	-	57.5
Rev LTM	0	11,723	-	0	-	-	0
Op Inc LTM	-58	-92	-	-7	-	-	-58
FCF LTM	-40	3,337	-	-7	-	-	-7
FCF 3Y Avg	-57	2,064	-	-8	-	-	-8
CFO LTM	-40	3,718	-	-7	-	-	-7
CFO 3Y Avg	-57	2,419	-	-8	-	-	-8

Growth & Margins

	RLMD	VRTX	ACSB	AIXC	ALPS	APRI	Median
Name	Relmada .	Vertex P.	Acesis	AIxCrypto	ALPS	Aprinoia.
Rev Chg LTM	-	10.3%	-	-	-	-	10.3%
Rev Chg 3Y Avg	-	10.5%	-	-	-	-	10.5%
Rev Chg Q	-	11.0%	-	-	-	-	11.0%
QoQ Delta Rev Chg LTM	-	2.7%	-	-	-	-	2.7%
Op Mgn LTM	-	-0.8%	-	-	-	-	-0.8%
Op Mgn 3Y Avg	-	26.2%	-	-	-	-	26.2%
QoQ Delta Op Mgn LTM	-	1.0%	-	-	-	-	1.0%
CFO/Rev LTM	-	31.7%	-	-	-	-	31.7%
CFO/Rev 3Y Avg	-	23.1%	-	-	-	-	23.1%
FCF/Rev LTM	-	28.5%	-	-	-	-	28.5%
FCF/Rev 3Y Avg	-	19.8%	-	-	-	-	19.8%

Valuation

	RLMD	VRTX	ACSB	AIXC	ALPS	APRI	Median
Name	Relmada .	Vertex P.	Acesis	AIxCrypto	ALPS	Aprinoia.
Mkt Cap	0.1	114.9	-	-	-	-	57.5
P/S	-	8.5	-	-	-	-	8.5
P/EBIT	-	22.4	-	-	-	-	22.4
P/E	-1.2	27.2	-	-	-	-	13.0
P/CFO	-1.7	26.9	-	-	-	-	12.6
Total Yield	-84.2%	3.7%	-	-	-	-	-40.3%
Dividend Yield	0.0%	0.0%	-	-	-	-	0.0%
FCF Yield 3Y Avg	-	2.3%	-	-	-	-	2.3%
D/E	-	0.0	-	-	-	-	0.0
Net D/E	-	-0.0	-	-	-	-	-0.0

Returns

	RLMD	VRTX	ACSB	AIXC	ALPS	APRI	Median
Name	Relmada .	Vertex P.	Acesis	AIxCrypto	ALPS	Aprinoia.
1M Rtn	1.0%	3.6%	-	-	9.5%	-	3.6%
3M Rtn	165.6%	16.1%	-	-	-	-	90.8%
6M Rtn	472.9%	0.2%	-	-	-	-	236.6%
12M Rtn	1,008.7%	-4.2%	-	-	-	-	502.2%
3Y Rtn	19.0%	47.5%	-	-	-	-	33.2%
1M Excs Rtn	0.3%	2.8%	-	-	8.8%	-	2.8%
3M Excs Rtn	141.7%	14.8%	-	-	-	-	78.2%
6M Excs Rtn	460.6%	-12.1%	-	-	-	-	224.2%
12M Excs Rtn	981.6%	-14.1%	-	-	-	-	483.7%
3Y Excs Rtn	-50.1%	-25.4%	-	-	-	-	-37.8%

Financials

Annual
Quarterly

$ Mil \| FY: 12/31	LTM	2024	2023	2022	2021	2020	2019
Period End	9/30/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019
Filing Date	11/13/2025	3/27/2025	3/19/2024	3/23/2023	3/25/2022	3/24/2021	3/26/2020
Key Financials
Total Revenue	0	0	0	0	0	0	0
EBITDA	-58	-84	-104	-161	-126	-61	-8
Operating Income	-58	-84	-104	-161	-126	-61	-8
Net Income	-56	-80	-99	-157	-126	-59	-8
EPS	-1.80	-2.65	-3.28	-5.30	-7.16	-3.81	-0.77
Growth Rates
Total Revenue Growth	-	-	-	-	-	-	-
EBITDA Growth	36.9%	19.1%	35.7%	-28.3%	-106.6%	-635.7%	35.0%
Operating Income Growth	36.9%	19.1%	35.7%	-28.3%	-106.6%	-635.5%	35.0%
Net Income Growth	35.0%	19.0%	37.1%	-24.9%	-111.5%	-625.4%	52.7%
Margins
EBITDA Margin	-	-	-	-	-	-	-
Operating Income Margin	-	-	-	-	-	-	-
Net Income Margin	-	-	-	-	-	-	-
Cash & Debt
Total Cash	14	45	96	148	212	117	116
Total Debt	0	0	0	0	0	0	0
Net Debt / (Cash)	-14	-45	-96	-148	-212	-117	-116
Cash Flows
Net Cash from Operations	-40	-52	-52	-104	-92	-28	-6
Free Cash from Operations	-40	-52	-52	-104	-92	-28	-6
Returns to Shareholders
Dividends	0	-0	-0	-0	-0	-0	-0
Share Repurchases	-0	-0	-0	-0	-0	-0	-0

null

Segment Financials

Assets by Segment

$ Mil	2024	2023	2022	2021	2020
Clinical stage drug development	98	153	223	118	117
Total	98	153	223	118	117

Price Behavior

Price Behavior

Market Price	$4.01
Market Cap ($ Bil)	0.1
First Trading Date	03/16/2018
Distance from 52W High	-11.1%
	50 Days	200 Days
DMA Price	$3.26	$1.36
DMA Trend	up	up
Distance from DMA	23.1%	194.5%
	3M	1YR
Volatility	119.1%	154.0%
Downside Capture	55.76	-62.87
Upside Capture	551.77	185.36
Correlation (SPY)	15.5%	9.9%

RLMD Betas & Captures as of 11/30/2025

	1M	2M	3M	6M	1Y	3Y
Beta	-1.58	0.99	0.21	0.29	0.64	0.72
Up Beta	0.79	-0.33	-0.16	0.99	1.10	0.80
Down Beta	-1.11	-1.49	-1.02	-0.94	0.28	0.49
Up Capture	389%	757%	757%	504%	17%	22%
Bmk +ve Days	13	26	39	74	142	427
Stock +ve Days	12	21	34	61	120	345
Down Capture	-681%	14%	-293%	-295%	-27%	87%
Bmk -ve Days	7	16	24	52	107	323
Stock -ve Days	8	19	27	62	126	374

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

1Y 5Y 10Y

Based On 1-Year Data

		Comparison of RLMD With Other Asset Classes (Last 1Y)
	RLMD	Sector ETF	Equity	Gold	Commodities	Real Estate	Bitcoin
Annualized Return	983.8%	10.5%	12.1%	61.5%	2.2%	-2.2%	-12.7%
Annualized Volatility	153.4%	17.4%	19.7%	19.3%	15.9%	17.7%	35.4%
Sharpe Ratio	2.22	0.41	0.46	2.36	-0.05	-0.28	-0.17
Correlation With Other Assets		7.8%	10.2%	-4.9%	3.0%	5.2%	-3.3%

ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How

Based On 5-Year Data

		Comparison of RLMD With Other Asset Classes (Last 5Y)
	RLMD	Sector ETF	Equity	Gold	Commodities	Real Estate	Bitcoin
Annualized Return	-35.2%	8.1%	14.4%	18.3%	11.4%	4.8%	36.3%
Annualized Volatility	112.0%	14.5%	17.1%	15.5%	18.9%	18.9%	48.9%
Sharpe Ratio	0.29	0.38	0.68	0.95	0.49	0.17	0.63
Correlation With Other Assets		7.5%	9.7%	-0.6%	1.5%	9.6%	2.0%

Based On 10-Year Data

		Comparison of RLMD With Other Asset Classes (Last 10Y)
	RLMD	Sector ETF	Equity	Gold	Commodities	Real Estate	Bitcoin
Annualized Return	25.4%	9.9%	14.5%	14.6%	6.1%	5.4%	70.7%
Annualized Volatility	167.8%	16.7%	18.0%	14.7%	17.7%	20.8%	55.9%
Sharpe Ratio	0.76	0.49	0.69	0.82	0.27	0.23	0.91
Correlation With Other Assets		10.7%	10.1%	-2.6%	2.0%	9.3%	2.7%

Short Interest

Short Interest: As Of Date	11282025
Short Interest: Shares Quantity	772,889
Short Interest: % Change Since 11152025	-18.3%
Average Daily Volume	998,082
Days-to-Cover Short Interest	1
Basic Shares Quantity	33,191,622
Short % of Basic Shares	2.3%

Earnings Returns History

Expand for More

	Forward Returns
Earnings Date	1D Returns	5D Returns	21D Returns
11/13/2025	1.8%	11.3%
8/7/2025	-2.4%	0.9%	165.8%
3/27/2025	-0.4%	-7.4%	19.8%
3/19/2024	-17.4%	-12.7%	-19.9%
11/8/2023	-0.3%	1.0%	-14.7%
8/8/2023	7.1%	34.3%	39.8%
3/23/2023	-2.2%	-3.4%	8.2%
11/10/2022	8.7%	2.7%	-42.0%
...
SUMMARY STATS
# Positive	4	7	6
# Negative	6	3	4
Median Positive	7.3%	2.7%	14.0%
Median Negative	-2.3%	-7.4%	-19.9%
Max Positive	8.7%	34.3%	165.8%
Max Negative	-17.4%	-12.7%	-42.0%

	Forward Returns
11/13/2025	1.8%	11.3%
8/7/2025	-2.4%	0.9%	165.8%
3/27/2025	-0.4%	-7.4%	19.8%
3/19/2024	-17.4%	-12.7%	-19.9%
11/8/2023	-0.3%	1.0%	-14.7%
8/8/2023	7.1%	34.3%	39.8%
3/23/2023	-2.2%	-3.4%	8.2%
11/10/2022	8.7%	2.7%	-42.0%
3/23/2022	7.6%	11.7%	4.9%
3/23/2021	-7.2%	1.7%	7.9%
SUMMARY STATS
# Positive	4	7	6
# Negative	6	3	4
Median Positive	7.3%	2.7%	14.0%
Median Negative	-2.3%	-7.4%	-19.9%
Max Positive	8.7%	34.3%	165.8%
Max Negative	-17.4%	-12.7%	-42.0%

SEC Filings

Expand for More

Report Date	Filing Date	Filing
9302025	11132025	10-Q 9/30/2025
6302025	8072025	10-Q 6/30/2025
3312025	5122025	10-Q 3/31/2025
12312024	3272025	10-K 12/31/2024
9302024	11072024	10-Q 9/30/2024
6302024	8072024	10-Q 6/30/2024
3312024	5082024	10-Q 3/31/2024
12312023	3192024	10-K 12/31/2023
9302023	11082023	10-Q 9/30/2023
6302023	8082023	10-Q 6/30/2023
3312023	5112023	10-Q 3/31/2023
12312022	3232023	10-K 12/31/2022
9302022	11102022	10-Q 9/30/2022
6302022	8112022	10-Q 6/30/2022
3312022	5052022	10-Q 3/31/2022
12312021	3252022	10-K 12/31/2021

Industry Resources

Health Care Resources

U.S. National Library of Medicine

Health Data Management

FDA Tracker

Biotechnology Resources

Fierce Biotech

Nature Biotechnology

Genetic Engineering & Biotechnology News

Biotechnology Innovation Organization

BioWorld

BioTechniques

HBS Biotechnology Publications

External Quote Links

0	Y Finance	Barrons
1	TradingView	Morningstar
2	SeekingAlpha	ValueLine
3	Motley Fool	Robinhood
4	CNBC	Etrade
5	MarketWatch	Unusual Whales
6	YCharts	Perplexity Finance
7	FinViz

Prefer one of these to Trefis? Tell us why.

Relmada Therapeutics (RLMD)

Market Price (12/18/2025): $4.005 | Market Cap: $132.9 MilSector: Health Care | Industry: Biotechnology

Relmada Therapeutics (RLMD)

Market Price (12/18/2025): $4.005Market Cap: $132.9 MilSector: Health CareIndustry: Biotechnology

Valuation, Metrics & Events

RLMD Stock

Why The Stock Moved

Qualitative Assessment

Stock Movement Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Return vs. Risk

Price Returns Compared

How Low Can It Go

In The Past

Preserve Wealth

Asset Allocation

About Relmada Therapeutics (RLMD)

Key Business Risks for Relmada Therapeutics (RLMD)

Share Issuance

Outbound Investments

Capital Expenditures

Interactive Breakdown

Better Bets than Relmada Therapeutics (RLMD)

Latest Trefis Analyses

Trade Ideas

Recent Active Movers

1 Day Top Gainers

1 Day Top Losers

1 Week Top Gainers

1 Week Top Losers

1 Month Top Gainers

1 Month Top Losers

Recent Active Movers

1 Day Top Gainers

1 Day Top Losers

1 Week Top Gainers

1 Week Top Losers

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons for Relmada Therapeutics

Financials

Growth & Margins

Valuation

Returns

Comparison Analyses

FDIC Bank Data

Bank Capital

Bank Deposits

Bank Assets

Bank Loans

Financials

Segment Financials

Price Behavior

Based On 1-Year Data

Based On 5-Year Data

Based On 10-Year Data

Short Interest

Returns Analyses

Earnings Returns History

SEC Filings

Insider Activity

Industry Resources

External Quote Links

Market Price (12/18/2025): $4.005 | Market Cap: $132.9 Mil
Sector: Health Care | Industry: Biotechnology

Market Price (12/18/2025): $4.005
Market Cap: $132.9 Mil
Sector: Health Care
Industry: Biotechnology